When developing a new drug, there is a risk that the trial can be interrupted at any stage, even after the drug has started selling, and it is almost impossible to predict this failure.

The approach developed by us takes maximum account of the experimental material accumulated over 15 years by foreign companies in development of modern anticoagulants, so it can be predicted that the probability of failure is significantly lower than in case of development of other categories of drugs. In addition, it is necessary to take into account the fact that with every further step the probability of failure of the project as a whole decreases.